Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 4/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.32 |
| ▸ | TIPARP | Q7Z3E1 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
| ▸ | CASP3 | P42574 | 1/20 | 0.30 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5161302 | 0.86 | ADORA2A (0.38) | ADORA2AADORA1HRH3ALDH1A1ADRA1A | |
| SCHEMBL5160884 | 0.85 | HRH3 (0.32) | ADORA2AADORA1HRH3 | |
| Hydrochloric Acid SCHEMBL5163245 | 0.85 | ADORA2A (0.42) | ADORA2AADORA1ADRA1ACRHR1 | |
| Hydrochloric Acid SCHEMBL5424240 | 0.81 | HRH3 (0.36) | ADORA2AADORA1HRH3ALDH1A1 | |
| SCHEMBL5161461 | 0.79 | HRH3 (0.32) | HRH3ALDH1A1 | |
| SCHEMBL5162622 | 0.78 | HRH3 (0.33) | HRH3ALDH1A1 | |
| SCHEMBL5162229 | 0.77 | HRH3 (0.33) | HRH3ALDH1A1 | |
| SCHEMBL5418198 | 0.77 | HRH3 (0.37) | HRH3ALDH1A1 | |
| SCHEMBL5161501 | 0.77 | HRH3 (0.37) | HRH3ALDH1A1 | |
| Hydrochloric Acid SCHEMBL5158984 | 0.76 | HRH3 (0.36) | HRH3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070232601-A1 | Vla-4 Inhibitor | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-10-04 | — | — | US | disclosed |
| EP-1757602-A1 | VLA-4 INHIBITOR | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232601-A1 | Vla-4 Inhibitor | VCAM1, ITGB4, ITGA4 | ADORA2A 3707/4885ADORA1 1528/4885HRH3 468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.